Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (original) A compound of formula I



I

wherein

X is O, S, N-CH_3, CH=CH or CAlk = CAlk, where the Alk independently are (C_{1-4})alkyl,

R_1 and R_2 independently, are hydrogen, halogen, (C_{1-4})alkyl, (C_{1-4})alkoxy or trifluoromethyl, and

Het is a radical having one of the formulae (a) to (p) below:



(a) (b) (c) (d)

(e) (f) (g) (h)

(i) (j) (k) (l)



(m)



(n)



(o)



(p)

wherein

R_3 and R_8, independently, are hydrogen or (C_{1-4})alkyl,

R_4 is hydrogen, (C_{1-4})alkyl, cyano, nitro, formyl or (C_{1-4})alkylcarbonyl,

R_5 and R_6, independently, are hydrogen, (C_{1-7})alkyl, (C_{3-7})alkenyl, (C_{3-7})cycloalkyl, (C_{3-7})cycloalkyl(C_{1-4})alkyl, (C_{1-4})alkoxy(C_{2-5})alkyl or benzyl,

R_7 is hydrogen, hydroxy, (C_{1-4})alkyl or (C_{1-4})alkoxy,

W is N, C-CN, C-NO_2, C-COH or C-CO-Alk where Alk is as defined above, and

X is as defined above,

in free base or acid addition salt form

2. (original) 5,7-Dimethyl-4-[2,5-dimethyl-6-(di-n-propyl)-amino-pyrimidin-4-yl]amino-2,1,3-benzothiadiazole in free base or acid addition salt form.

3. (original) A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which includes the step of reacting a compound of formula II



II

wherein X, R_1 and R_2 are as defined in claim 1 and Y is a radical having one of the formulae (a') to (p') below:



(a')



(b')



(c')



(d')



wherein R_3 to R_8, W and X are as defined in claim 1 and Hal is halogen, with a compound of formula III



III

wherein R_5 and R_6 are as defined in claim 1, and recovering the thus obtained compound of formula I in free base or acid addition salt form.

4-9. (cancelled)

10. (currently amended) A compound of claim 1 which is [[*N*-(6-chloro-8-methyl-qunioxalin-5-yl)-*N'*-cyclopropylmethyl-2,5-dimethyl-*N'*-*n*-propyl-pyrimidine-4,6-diamine]] *N*-(6-chloro-8-methyl-quinoxalin-5-yl)-*N'*-cyclopropylmethyl-2,5-dimethyl-*N'*-*n*-propyl-pyrimidine-4,6-diamine, in free base or acid addition salt form.

11. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1, in free base or pharmaceutically acceptable acid addition salt form.

12. (new) A method of treating diseases which are responsive to the antagonism of CRF_1 receptors comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1, in free base or pharmaceutically acceptable acid addition salt form.